Despite evidence suggesting a general role for PI3K-AKT-mTOR pathway signaling in EGFR-mutant NSCLC, whether Akt activation, specifically, can drive acquired EGFR-TKI resistance has not been clearly demonstrated. The gene discussed is MTOR; the disease is non-small cell lung carcinoma.